November 10, 2020
FOR IMMEDIATE RELEASE
Contact: Joanie Manzo
Director, OHC Marketing & Physician Services
513-751-2273 EXT. 10143
OHC is excited to share that the US Food and Drug Administration has approved a new treatment for metastatic non-small cell lung cancer. This new treatment, which has been available at OHC since April through its clinical trials program, offers these patients another option to fight their lung cancer.
Lung cancer typically does not demonstrate any symptoms until it has reached a late stage when it’s more challenging to treat. Although OHC has seen significant advancements and outcomes especially with targeted therapies and immunotherapies, not all patents’ cancer responds to those treatments.
“This is why my OHC colleagues and I are excited about Gavreto,” said OHC’s Benjamin T. Herms, MD, medical oncologist and hematologist who specializes in lung cancer. “It’s a new FDA-approved treatment that gives us another option for patients whose cancer hasn’t responded to current treatments and are running out of options.”
Although it has just been approved by the FDA, it’s been available at OHC since April 2020 through their nationally recognized clinical trials program.
Gavreto (pralsetinib) is a targeted therapy that stops an enzyme known as RET that promotes cancer growth in metastatic non-small cell lung cancer (NSCLC) with specific gene alterations. It goes after the source – the RET enzyme – to stop it from promoting growth and therefore opening the possibility of an extended remission. In more than half of the patients, the drug didn’t just stop growth, it shrunk their tumors.
The lung cancer experts at OHC offer many promising new treatments for NSCLC through its nationally recognized clinical trials program. OHC was a leading cancer group that contributed to the FDA approval of the innovative lung cancer treatments, Opdivo and Keytruda. OHC has many patients who are doing remarkably well years later with these two treatments.Comments (0)